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Platinum cytostatics belong currently to the most widely used anticancer drugs. They 
are involved as a part of chemotherapy regiments in many indications. Cisplatin, as a 
first substance discovered in this group of cytostatics, was originally registered for the 
treatment of testicular cancer and ovarian cancer, but it is currently used in many other 
indications. The limiting factor associated with the administration of cisplatin is 
represented by adverse effects and the development of resistance in previously 
sensitive tumor cells. These factors stimulated further research in the field of platinum 
compounds in order to create a substance with similar mechanism of action, but better 
properties. To date, more than thirty agents entered clinical trials, but only two of them 
are used worldwide - carboplatin and oxaliplatin. The aim of this thesis is to create a 
publication that summarizes current knowledge on platinum cytostatics, which are used 
in the pharmacotherapy of cancer. This work focuses especially on the comparison 
between the various representatives under several scales (modes of action, 
mechanisms of resistance, pharmacokinetics, adverse effects and application in 
therapy). Understanding the relation between the structure of substances, cellular 
processes, mechanisms of resistance and therapeutic use of platinium drugs is 
important for the future research that may be focused on overcoming of resistance, 
minimization of adverse effects and increase of the efficiency of platinum compounds in 
pharmacotherapy of tumors. 
